Novavax, Inc
Novavax is a U.S.-based biotechnology company focused on developing and commercializing protein-based vaccines and vaccine-related technologies. Its core business centers on its COVID-19 vaccine franchise, recombinant nanoparticle vaccine platform, and Matrix-M adjuvant, supported through collaborations with pharmaceutical partners and government procurement arrangements.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCommercial and government-supplied COVID-19 vaccine products and related formulations.
Revenue from collaboration agreements, milestone achievements, and royalty streams.
Sales of Matrix-M adjuvant and other materials supplied to partners.
Services provided to partners during product transfer and commercialization transitions.
Products
Reported · share of revenue- Nuvaxovid Sales55.6 %
- Licensing Royalties and Other39.0 %
- Supply Sales5.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Novavax sells primarily to pharmaceutical partners, governments, and wholesale distributors rather than directly to a broad consumer base. Its revenue is driven by vaccine procurement agreements, collaboration partners that commercialize or distribute products, and counterparties that pay licensing or milestone fees tied to development and regulatory progress.
Buy vaccine doses under APAs and settlement arrangements to support public immunization programs.
License Novavax technology, fund development, and commercialize products in specific markets.
Distribute commercial vaccine supply in markets where Novavax or a partner is the commercial lead.
Purchase adjuvant, materials, and related supply items for use in partner vaccine programs.
Strategy
Novavax’s strategy is centered on its COVID-19 vaccine franchise, partner-led commercialization, and monetization of its Matrix-M platform through collaborations and licensing. The company also seeks to extend its technology into additional vaccine programs and therapeutic areas while relying on external partners for distribution, manufacturing, and market access.
Partner-led distribution reduces the need for a large direct sales force and broadens market access.
Licensing and supply agreements create non-dilutive revenue from the adjuvant technology base.
Broader pipeline development can diversify revenue and reduce dependence on one vaccine franchise.
Geography
Q1/2026Novavax is headquartered in the United States but operates through a global collaboration and supply network. Its business is international in nature, with agreements and commercial activity spanning North America, Europe, and Asia through partners and government counterparties.
Share of the revenue the company reports by geography.
Risks
Novavax faces substantial execution and funding risk because its business depends on successful vaccine development, partner performance, and continued access to capital. It is also exposed to regulatory, competitive, and international operating risks, including product approval timing, supply-chain complexity, and foreign government or collaborator concentration.
- Funding and going-concern riskImpact: CriticalLikelihood: High
The company requires significant funding to maintain operations and advance its pipeline.
Exposure - Dependence on collaboration and supply agreementsImpact: HighLikelihood: High
Revenue and commercialization depend on third parties that control distribution, milestones, and market execution.
Exposure - Regulatory and clinical development riskImpact: HighLikelihood: High
Vaccine candidates must succeed in trials and obtain approvals before generating durable commercial value.
Exposure - Competitive pressureImpact: MediumLikelihood: High
Larger vaccine companies can move faster on development, manufacturing, and commercialization.
Exposure: COVID-19 and combination vaccine markets
- International operating and compliance riskImpact: MediumLikelihood: Medium
The company operates through cross-border agreements and faces local regulatory, tax, and anti-bribery requirements.
Exposure
Accounting
Judgemental itemsSanofi and other partner contracts include upfront payments, milestones, royalties, and services that may be recognized over time or at points in time.
Impact: Can create large swings in reported revenue between periods
Vaccine sales include estimates for returns and deductions, which can materially change net product revenue.
Impact: Affects the timing and amount of recognized product sales
Upfront collaboration payments and milestone receipts may be deferred until performance obligations are satisfied.
Impact: Can shift revenue recognition across quarters and years
APA terminations and dispute settlements can produce non-routine revenue or gains.
Impact: May distort comparability with underlying commercial demand
Similar listed companies
Publicly listed companies with a comparable business focus.
Dynavax Technologies Corp
Pharmaceutical Preparations
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Vaxart, Inc.
VXRT · Biological Products, (No Diagnostic Substances)
Moderna, Inc.
MRNA · Biological Products, (No Diagnostic Substances)
Pfizer, Inc
PFE · Pharmaceutical Preparations
Nuvation Bio Inc.
NUVB · Pharmaceutical Preparations
Last updated: 24/09/2026